Uterine activity in women receiving 17-hydroxyprogesterone caproate for the prevention of preterm birth: An observational study

American Journal of Perinatology

Volumn 27, Issue 2, 2010, Pages 157-162

  O'Brien, John M ^a   Ho, Shannon J ^b   Istwan, Niki B ^c   Stanziano, Gary J ^c   Rhea, Debbie J ^c   Barton, John R ^a  

^a CENTRAL BAPTIST HOSPITAL   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c Department of Clinical Research ^*  (Georgia)

Author keywords

17 hydroxyprogesterone caproate; Drug safety; Preterm birth; Uterine contractions

Indexed keywords

HYDROXYPROGESTERONE CAPROATE; NIFEDIPINE; TERBUTALINE;

ADULT; ARTICLE; CONTROLLED STUDY; DELIVERY; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; TOCOLYSIS; UTERUS CONTRACTION;

ADULT; FEMALE; HUMANS; HYDROXYPROGESTERONES; INJECTIONS; PREGNANCY; PREMATURE BIRTH; PROGESTINS; RETROSPECTIVE STUDIES; UTERINE CONTRACTION;

EID: 76249124340     PISSN: 07351631     EISSN: 10988785     Source Type: Journal    
DOI: 10.1055/s-0029-1234033     Document Type: Article

References (16)

1. Meis P J., Klebanoff M, Thom E et al, National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003 348 2379-2385
2. Fonseca E B., Celik E, Parra M, Singh M, Nicolaides K H., Fetal Medicine Foundation Second Trimester Screening Group. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 2007 357 462-469
3. da Fonseca E B., Bittar R E., Carvalho M H., Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003 188 419-424
4. DeFranco E A., O'Brien J M., Adair C D. et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007 30 697-705
5. Sharma S, Ou J, Strom S C., Mattison D, Caritis S, Venkataramanan R. Identification of enzymes involved in the metabolism of 17alpha- hydroxyprogesterone caproate: an effective agent for prevention of preterm birth. Drug Metab Dispos 2008 36 1896-1902
6. Xu H, Gonzalez J M., Ofori E, Elovitz M A. Preventing cervical ripening: the primary mechanism by which progestational agents prevent preterm birth? Am J Obstet Gynecol 2008 198 314.e1-314.e8
7. Marx S G., Wentz M J., Mackay L B. et al. Effects of progesterone on iNOS, COX-2, and collagen expression in the cervix. J Histochem Cytochem 2006 54 623-639
8. Hardy D B., Janowski B A., Corey D R., Mendelson C R. Progesterone receptor plays a major antiinflammatory role in human myometrial cells by antagonism of nuclear factor-kappaB activation of cyclooxygenase 2 expression. Mol Endocrinol 2006 20 2724-2733
9. Cakmak H, Schatz F, Huang S T. et al. Progestin suppresses thrombin-and interleukin-1beta-induced interleukin-11 production in term decidual cells: implications for preterm delivery. J Clin Endocrinol Metab 2005 90 5279-5286
10. Ou C W., Orsino A, Lye S J. Expression of connexin-43 and connexin-26 in the rat myometrium during pregnancy and labor is differentially regulated by mechanical and hormonal signals. Endocrinology 1997 138 5398-5407
11. Facchinetti F, Paganelli S, Comitini G, Dante G, Volpe A. Cervical length changes during preterm cervical ripening: effects of 17-alpha- hydroxyprogesterone caproate. Am J Obstet Gynecol 2007 196 453.e1-453.e4 discussion 421
12. Attardi B, Zeleznik A, Simhan H et al. Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins. Am J Obstet Gynecol 2007 197 599.e1-599.e7
13. Ruddock N, Shi S-Q, Jain S et al. Progesterone, but not 17 alpha hydroxyprogesterone caproate, inhibits human myometrial contractions. Am J Obstet Gynecol 2008 199 391.e1-391.e7
14. Sexton D J., O'Reilly M W., Friel A M., Morrison J J. Functional effects of 17alpha-hydroxyprogesterone caproate (17P) on human myometrial contractility in vitro. Reprod Biol Endocrinol 2004 2 80
15. Iams J D., Newman R B., Thom E A. et al, National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Frequency of uterine contractions and the risk of spontaneous preterm delivery. N Engl J Med 2002 346 250-255
16. Institute of Medicine. Preterm Birth: Causes, Consequences, and Prevention Behrman RE, Butler AS Washington, DC National Academies Press 2006